| Nicole C Stephens, MD | |
|
920 E High St Ste 201, Charlottesville, VA 22902-4850 | |
| (434) 654-1950 | |
| Not Available |
| Full Name | Nicole C Stephens |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 920 E High St Ste 201, Charlottesville, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770014037 | NPI | - | NPPES |
| Entity Name | Martha Jefferson Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275720559 PECOS PAC ID: 5991889081 Enrollment ID: O20080228000055 |
News Archive
Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the launch of piperacillin and tazobactam for injection in the United States. The medication is a generic version of Zosyn, the world's leading injectable antibiotic, from Pfizer. Piperacillin and tazobactam injection posted 2009 U.S. sales of more than $855 million.
Emotions adjust our mental and also bodily states to cope with the challenges detected in the environment. These sensations arising from the bodily changes are an important feature of our emotional experiences.
Cerus Corporation announced today that it has entered into an agreement with CSL Limited, Biotherapies division to distribute Cerus' INTERCEPT Blood System for platelets in Australia and New Zealand. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens, including bacteria and emerging pathogens such as the dengue and chikungunya viruses.
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole C Stephens, MD 920 E High St Ste 201, Charlottesville, VA 22902-4850 Ph: (434) 654-1950 | Nicole C Stephens, MD 920 E High St Ste 201, Charlottesville, VA 22902-4850 Ph: (434) 654-1950 |
News Archive
Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the launch of piperacillin and tazobactam for injection in the United States. The medication is a generic version of Zosyn, the world's leading injectable antibiotic, from Pfizer. Piperacillin and tazobactam injection posted 2009 U.S. sales of more than $855 million.
Emotions adjust our mental and also bodily states to cope with the challenges detected in the environment. These sensations arising from the bodily changes are an important feature of our emotional experiences.
Cerus Corporation announced today that it has entered into an agreement with CSL Limited, Biotherapies division to distribute Cerus' INTERCEPT Blood System for platelets in Australia and New Zealand. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens, including bacteria and emerging pathogens such as the dengue and chikungunya viruses.
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
› Verified 2 days ago
Donald J. Dudley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 W Main St, Charlottesville, VA 22908 Phone: 434-924-2500 Fax: 434-244-9487 | |
Christian A. Chisholm, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 W Main St, Charlottesville, VA 22903 Phone: 434-924-2500 Fax: 434-244-9487 | |
Jennifer Doorey, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2955 Ivy Rd Ste 304, Charlottesville, VA 22903 Phone: 434-243-4570 Fax: 434-295-5491 | |
Evan Jacob Kraus, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 600 Peter Jefferson Pkwy, Charlottesville, VA 22911 Phone: 434-977-4488 | |
Charles N. Landen Jr., M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1240 Lee St, Charlottesville, VA 22908 Phone: 434-924-5100 Fax: 434-982-1840 | |
Dr. Linnea Rose Goodman, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4100 Olympia Cir Ste 201, Charlottesville, VA 22911 Phone: 434-220-6620 Fax: 434-220-6621 | |
Ms. Whitney Dijon Archie-patrick, FNP Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2955 Ivy Rd Ste 304, Charlottesville, VA 22903 Phone: 434-243-4570 Fax: 434-295-5491 |